今年的ASCO年会将于5月31日至6月4日在芝加哥隆重开幕，会议以““The Art and Science of Cancer Care: From Comfort to Cure”为主题，强调了跨学科、跨领域的合作与交流在肿瘤防治中的重要性。
会议期间，将举办一系列精彩的学术报告、专题研讨和互动活动，涵盖肿瘤学领域的最新进展、创新药物研发、个性化治疗等多个热点话题。在为期数天的会议中，与会者们将围绕肿瘤防治的多个方面展开深入研讨，分享创新理念和实践经验，共同为攻克癌症这一人类健康难题贡献智慧。
中国学者敢于争先，屡次在历届ASCO中传播中国之声。在此，【肿瘤资讯】特将肺癌领域中国学者的上榜研究进行报道，以期为国内外同行提供最新的科研信息。
口头报告
摘要号：8004
讲者：王思愚（中山大学肿瘤防治中心）
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.
可切除EGFR突变II-IIIA期非小细胞肺癌（NSCLC）接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验（ICTAN，GASTO1002）
摘要号：8008
讲者：刘慧（中山大学肿瘤防治中心）
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).
一项评估局部晚期NSCLC新辅助化疗联合纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验（GASTO-1091）
摘要号：8009
讲者：Pan-Chyr Yang（台湾大学医学院）
Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.
台湾地区对于重度吸烟以及有肺癌家族史的非吸烟人群肺癌早期检测计划
摘要号：8502
讲者：方文峰（中山大学肿瘤防治中心）
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.
II期OptiTROP-Lung01研究：Sacituzumab tirumotecan（SKB264/MK-2870）联合KL-A167（抗PD-L1）作为中晚期NSCLC患者的一线治疗
摘要号：8508
讲者：张力（中山大学肿瘤防治中心）
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
依沃西单抗联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者：一项随机、双盲、多中心、III期试验（HARMONi-A）
临床科学研讨会
摘要号：LBA8509
讲者：莫树锦（香港中文大学）
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
III期KRYSTAL-12研究：adagrasib对比多西他赛治疗经治的KRAS G12C突变晚期/转移性NSCLC患者
快速口头摘要会议
摘要号：8014
讲者：陈大卫（山东第一医科大学附属肿瘤医院）
Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.
阿得贝利单抗联合化疗和序贯胸部放疗作为广泛期小细胞肺癌（ES-SCLC）的一线治疗的总生存期（OS）
摘要号：8513
讲者：杨志新（中国国立台湾大学肿瘤中心医院）
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.
舒沃替尼治疗含铂化疗失败的EGFR exon 20ins NSCLC：一项国际多中心注册临床研究，WU-KONG1研究的初步分析结果
摘要号：8520
讲者：李玮（上海市肺科医院）
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.
taletrectinib治疗晚期或转移性ROS1阳性NSCLC患者的疗效和安全性：II期TRUST-I研究
壁报
摘要号：8024
讲者：Ting Wang
A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).
替雷利珠单抗（TIS）和化疗新辅助治疗可切除的IIIA/IIIB期NSCLC的II期研究
摘要号：8027
讲者：Yu-Heng Zhou（中山大学肿瘤防治中心）
Investigation of the role of personalized molecular residual disease in the assessment of high-risk non-small cell lung cancer (NSCLC) post-operation.cancer: A systematic review and meta-analysis of randomized clinical trials.
个体化MRD在高危NSCLC术后评估中的作用研究：一项随机临床试验的系统回顾和荟萃分析
摘要号：8044
讲者：Suyu Wang（同济大学附属上海市肺科医院）
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.
PD-1抗体联合铂类双联化疗诱导治疗局部晚期NSCLC：一项随机对照、开放标签的II期临床试验
摘要号：8048
讲者：邱福铭（浙江大学医学院附属第二医院）
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.
随机II期neoSCORE试验的最终生存结果和探索性生物标志物分析：信迪利单抗联合化疗新辅助治疗可切除NSCLC两个周期与三个周期的比较
摘要号：8054
讲者：丁乃昕（南京医科大学附属肿瘤医院）
Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.
大分割放疗联合帕博利珠单抗和化疗新辅助治疗可切除的NSCLC：一项Ib期研究
摘要号：8058
讲者：Min Tang（中国医学科学院老年医学研究所国家老年医学中心）
The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer.
诱导化学免疫治疗在不可切除的III期NSCLC中的安全性和有效性
摘要号：8062
讲者：Lin Wu
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.
安罗替尼联合多西紫杉醇治疗晚期NSCLC的免疫治疗进展：两项随机试验的汇总分析
摘要号：8065
讲者：邱波（中山大学肿瘤防治中心）
A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).
在局部晚期NSCLC中，新辅助化疗联合替雷利珠单抗±贝伐珠单抗，然后进行大分割放疗，同时化疗和巩固免疫治疗的II期双队列研究（GASTO-1086）
摘要号：8073
讲者：Yana Qi（山东省肿瘤医院）
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.
新辅助化学免疫疗法治疗不可切除的III期NSCLC后序贯手术切除的疗效和手术安全性
摘要号：8077
讲者：Shen Zhao（中山大学肿瘤防治中心）
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
aurora激酶A（AURKA）抑制剂VIC-1911联合奥希替尼治疗TKI耐药、EGFR突变NSCLC的I期临床试验
摘要号：8081
讲者：Sangtian Liu（广州医科大学第一附属医院）
EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.
EGFR-TKI作为EGFR敏感突变NSCLC患者的新辅助治疗：一项回顾性现实世界分析
摘要号：8082
讲者：吴一龙（广东省人民医院）
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.
新辅助SHR-1701在不可切除的III期NSCLC中有或没有化疗：概念验证II期试验（TRAILBLAZER）中手术转换结果的有效性，安全性和可行性
摘要号：8086
讲者：田亚如（山东省肿瘤医院）
Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.
PD-L1抑制剂与PD-1抑制剂用于ES-SCLC的一线治疗：倾向评分匹配研究
摘要号：8089
讲者：虞永峰（上海市胸科医院）
Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study
Tifcemalimab联合特瑞普利单抗和化疗作为ES-SCLC的一线治疗：Ib/II期开放标签研究
摘要号：8093
讲者：王洁（中国医学科学院肿瘤医院）
ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).
ARTEMIS-001:HS-20093在复发性SCLC患者中的Ia/b期研究数据
摘要号：8095
讲者：陆舜（上海交通大学附属胸科医院）
Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.
抗PD-L1联合化疗治疗ES-SCLC的III期临床试验结果
摘要号：8098
讲者：邱波（中山大学肿瘤防治中心）
A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.
LS-SCLC同步放化疗后特瑞普利单抗巩固或观察的随机II期研究
摘要号：8100
讲者：程颖（吉林省肿瘤医院）
Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.
斯鲁利单抗与安慰剂联合化疗作为ES-SCLC一线治疗的比较：国际ASTRUM-005III期研究的延伸随访结果和患者报告结果
摘要号：8102
讲者：虞永峰（上海市胸科医院）
An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).
ATR抑制剂SC0245联合伊立替康治疗复发难治性ES-SCLC的开放标签、多中心、Ib/II期研究
摘要号：TPS8117
讲者：Feng Tan（中国医学科学院北京协和医学院肿瘤医院）
Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).
阿美替尼联合或不联合化疗辅助治疗完全切除后II-IIIA期NSCLC的疗效和安全性：第一个第三代EGFR-TKI对比化疗的III期临床研究（APEX）
摘要号：TPS8120
讲者：Sida Cheng（北京大学人民医院）
Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.
新辅助特瑞普利单抗联合化疗治疗EGFR突变的可切除II-IIIB期非鳞状NSCLC：一项多中心、多队列、探索性研究
摘要号：TPS8131
讲者：董忠谊（南方医科大学南方医院放射肿瘤科）
A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer.
adebrelimab联合化疗和同步放疗作为寡转移性ES-SCLC的一线治疗的II期探索性试验
摘要号：8533
讲者：吴春娇（吉林省肿瘤医院）
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
评估PM8002（一种靶向PD-L1和VEGF-A的双特异性抗体）作为晚期NSCLC患者的单一疗法的安全性和有效性的Ib/IIa期试验
摘要号：8542
讲者：韩宝惠（上海市胸科医院）
MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.
MEK抑制剂联合RTK抑制剂（曲美替尼联合安罗替尼）治疗非G12C KRAS突变型NSCLC：一种新策略
摘要号：8546
讲者：Jia Yu（上海市肺科医院）
Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.
Mefatinib作为EGFR突变阳性NSCLC的一线治疗：III期疗效和生物标志物研究
摘要号：8548
讲者：Yuping Sun
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.
Dato-DXd在中国晚期或转移性NSCLC患者中的应用：I/II期TROPION-PanTumor02研究结果
摘要号：8554
讲者：熊艳娟（天津医科大学肿瘤医院）
Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.
吉非替尼联合贝伐珠单抗和化疗一线治疗EGFR突变的晚期非鳞状NSCLC的Ib期临床研究
摘要号：8557
讲者：Jin-Ji Yan
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.
伯瑞替尼治疗MET外显子14跳跃突变晚期NSCLC的疗效和安全性：KUNPENG研究2.5年随访结果
摘要号：8563
讲者：Mengzhao Wang
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
舒沃替尼治疗EGFR外显子20插入突变的NSCLC患者血浆ctDNA生物标志物研究
摘要号：8587
讲者：陈海洋（河南省肿瘤医院）
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
高剂量伏美替尼治疗EGFR突变NSCLC和软脑膜转移患者：一项真实世界的研究
摘要号：8604
讲者：王洁（中国医学科学院肿瘤医院）
Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
EGFR/c-MET双特异性抗体MCLA-129在晚期NSCLC中的疗效和安全性
摘要号：8605
讲者：Zaiqi Wang
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.
ifebemtinib（IN10018）联合D-1553治疗KRAS G12C突变NSCLC的安全性和有效性：Ib/II期研究的结果
摘要号：8606
讲者：唐可京（中山大学附属第一医院）
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.
Amivantamab联合化疗对比化疗作为EGFR外显子20插入突变晚期NSCLC的一线治疗：PAPILLON 研究中国亚组分析
摘要号：8609
讲者：段旭华（郑州大学第一附属医院）
Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.
支气管动脉化疗栓塞（BACE）联合替雷利珠单抗治疗NSCLC的疗效和安全性：II期研究
摘要号：TPS8656
讲者：陆舜（上海交通大学附属胸科医院）
A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).
telisotuzumab vedotin与多西紫杉醇治疗c-Met过表达、EGFR野生型、局部晚期/转移性非鳞状NSCLC（TeliMET NSCLC-01）患者的III期全球研究
摘要号：TPS8662
讲者：杨云鹏（中山大学肿瘤防治中心）
TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations
TOP研究：一项III期、多中心、随机对照研究，奥希替尼联合卡铂和培美曲塞对比奥希替尼单药治疗伴有EGFR和TP53突变的晚期非鳞状NSCLC患者的疗效
*以上排名不分先后，按照摘要号进行排序，如有遗漏或任何问题，请留言
2024年 ASCO年会的脚步声离我们越来越近，
肿瘤资讯也会安排采编记者
第一时间为大家带来“热辣滚烫”的前沿进展
传递国内专家在国际舞台的风采
点击图片关注下方专栏，与【肿瘤资讯】不见不散！
苏公网安备 32059002004080号
